Karyopharm and menarini group announce orphan medicinal product designation from the european commission for selinexor for the treatment of myelofibrosis

Newton, mass. and florence, italy, oct. 31, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the menarini group ("menarini"), a privately-held, leading international pharmaceutical company, today announced that the european commission (ec) has granted orphan medicinal product designation for selinexor for the treatment of myelofibrosis (mf).
KPTI Ratings Summary
KPTI Quant Ranking